KANSL1
Basic information
Region (hg38): 17:46029916-46225389
Previous symbols: [ "KIAA1267" ]
Links
Phenotypes
GenCC
Source:
- Koolen-de Vries syndrome (Definitive), mode of inheritance: AD
- Koolen-de Vries syndrome (Strong), mode of inheritance: AD
- Koolen-de Vries syndrome due to a point mutation (Supportive), mode of inheritance: AD
- Koolen-de Vries syndrome (Definitive), mode of inheritance: AD
- Koolen-de Vries syndrome (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Koolen-de Vries syndrome | AD | Cardiovascular | The condition can involve congenital cardiac anomalies, and awareness may allow early management | Cardiovascular; Craniofacial; Dermatologic; Genitourinary; Musculoskeletal; Neurologic | 22482802; 22544363; 26306646; 28440867 |
ClinVar
This is a list of variants' phenotypes submitted to
- Koolen-de_Vries_syndrome (1038 variants)
- not_provided (261 variants)
- not_specified (192 variants)
- Inborn_genetic_diseases (149 variants)
- KANSL1-related_disorder (20 variants)
- Intellectual_disability (7 variants)
- See_cases (3 variants)
- Syndromic_intellectual_disability (2 variants)
- Dystonia,_early-onset,_and/or_spastic_paraplegia (1 variants)
- Craniosynostosis_syndrome (1 variants)
- Global_developmental_delay (1 variants)
- Neurodevelopmental_delay (1 variants)
- Chromatinopathy (1 variants)
- Dysplastic_corpus_callosum (1 variants)
- Congenital_myopathy (1 variants)
- Neurodevelopmental_abnormality (1 variants)
- Developmental_disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the KANSL1 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000015443.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 262 | 270 | ||||
| missense | 433 | 243 | 26 | 713 | ||
| nonsense | 13 | 14 | 36 | |||
| start loss | 1 | 1 | ||||
| frameshift | 50 | 22 | 15 | 87 | ||
| splice donor/acceptor (+/-2bp) | 19 | |||||
| Total | 74 | 51 | 465 | 507 | 29 |
Highest pathogenic variant AF is 0.00002912045
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| KANSL1 | protein_coding | protein_coding | ENST00000262419 | 14 | 195452 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 1.00 | 0.000285 | 125711 | 0 | 37 | 125748 | 0.000147 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 1.23 | 551 | 638 | 0.863 | 0.0000372 | 7091 |
| Missense in Polyphen | 144 | 227.12 | 0.63403 | 2429 | ||
| Synonymous | -0.806 | 258 | 242 | 1.07 | 0.0000134 | 2286 |
| Loss of Function | 5.75 | 6 | 49.8 | 0.120 | 0.00000327 | 531 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.0000289 | 0.0000289 |
| Ashkenazi Jewish | 0.000497 | 0.000496 |
| East Asian | 0.00 | 0.00 |
| Finnish | 0.000601 | 0.000601 |
| European (Non-Finnish) | 0.000116 | 0.000114 |
| Middle Eastern | 0.00 | 0.00 |
| South Asian | 0.000163 | 0.000163 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: As part of the NSL complex it is involved in acetylation of nucleosomal histone H4 on several lysine residues and therefore may be involved in the regulation of transcription. {ECO:0000269|PubMed:20018852, ECO:0000269|PubMed:22547026}.;
- Pathway
- Pathways Affected in Adenoid Cystic Carcinoma;Chromatin modifying enzymes;HATs acetylate histones;Chromatin organization
(Consensus)
Recessive Scores
- pRec
- 0.137
Intolerance Scores
- loftool
- rvis_EVS
- -0.32
- rvis_percentile_EVS
- 30.95
Haploinsufficiency Scores
- pHI
- 0.602
- hipred
- Y
- hipred_score
- 0.741
- ghis
- 0.543
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.114
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | High | High | High |
| Primary Immunodeficiency | High | High | High |
| Cancer | High | High | High |
Mouse Genome Informatics
- Gene name
- Kansl1
- Phenotype
- nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);
Gene ontology
- Biological process
- histone H4-K5 acetylation;histone H4-K8 acetylation;histone H4-K16 acetylation
- Cellular component
- histone acetyltransferase complex;condensed chromosome kinetochore;nucleus;nucleoplasm;NSL complex;MLL1 complex
- Molecular function
- protein binding;histone acetyltransferase binding;histone acetyltransferase activity (H4-K5 specific);histone acetyltransferase activity (H4-K8 specific);histone acetyltransferase activity (H4-K16 specific)